Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/Latest News/Shocking Battle: Why the Maker of ‘Magic’ Weight-Loss Drug Semaglutide Fights to Ban Copycats
Latest News

Shocking Battle: Why the Maker of ‘Magic’ Weight-Loss Drug Semaglutide Fights to Ban Copycats

By adminitfy
November 14, 2024 2 Min Read

Novo Nordisk, the Danish pharmaceutical company behind the weight-loss drug Wegovy and diabetes medication Ozempic, has urged the US authorities to halt the compounding of these drugs, citing serious safety concerns. Compounding involves licensed pharmacists or physicians modifying or combining medication ingredients to meet patient needs, especially when branded versions are scarce. Due to high demand, US pharmacies have been producing compounded versions of these drugs, which contain semaglutide.

Novo Nordisk has expressed concerns over the safety of these compounded versions and has taken legal action against clinics and pharmacies, citing reports of at least 10 deaths and over 100 hospitalizations from compounded products. In response, the company has filed a request with the US FDA to list semaglutide on the Demonstrable Difficulties for Compounding (DDC) list, which restricts compounding when commercial versions are available.

Novo Nordisk highlights key issues with compounded semaglutide:

  1. Complex Formulation: The drug’s intricate structure, created with recombinant DNA technology, is hard to replicate accurately, potentially affecting purity and effectiveness.

  2. Delivery Mechanism: The FDA-approved version uses advanced delivery methods, such as single-use pen injectors, ensuring correct dosage and safety. Compounded versions may lack such precision, raising the risk of dosing errors.

  3. Bioavailability: Semaglutide’s naturally low bioavailability means compounded versions may not be absorbed properly, compromising treatment efficacy.

  4. Contamination and Stability Risks: Compounding requires specialized equipment to prevent contamination. Additionally, semaglutide is temperature-sensitive, and improper storage can affect its stability.

Novo Nordisk’s appeal comes as it emphasizes patient safety concerns amid growing reports of adverse effects linked to compounded semaglutide. The FDA has yet to rule on this request, as similar challenges by competitor Eli Lilly also remain unresolved.

Original Story https://indianexpress.com/article/explained/explained-health/why-maker-of-magic-weight-loss-drug-semaglutide-wants-copies-banned-9668561/
Category : Explained,Explained Health
Tags:
Publish Date: 2024-11-14 06:00:00

Author

adminitfy

Follow Me
Other Articles
Previous

Shocking Engineering Seat Blocking Scam Unveiled: FIR Targets Culprit IP Addresses!

Next

Shocking News: Trump Boldly Chooses Rep. Matt Gaetz as Attorney General!

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • অসমৰ সাংস্কৃতিক-আধ্যাত্মিক ঐতিহ্য আৰু শৈক্ষিক পৰিৱেশৰ নতুন যুগ
    অসমৰ সাংস্কৃতিক-আধ্যাত্মিক ঐতিহ্য আৰু শৈক্ষিক পৰিৱেশৰ নতুন যুগ
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • অসমৰ সাংস্কৃতিক-আধ্যাত্মিক ঐতিহ্য আৰু শৈক্ষিক পৰিৱেশৰ নতুন যুগ
  • Platform Trust and the AI Pricing Reset: Lessons from Microsoft Ignite
  • Drizzle No Bar as Urban Challenge Opens to Packed DDSC Gallery
  • Exclusive: Ajay Devgn & Bhushan Kumar’s 2028 Big-Budget Spy Thriller Talks Spark Blockbuster Buzz!
  • 49th Junior National Badminton Championships End with Grand Closing
  • November 2026 (671)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.